PMV PHARMACEUTICALS, INC. Increase (Decrease) in Prepaid Expense and Other Assets
PMV PHARMACEUTICALS, INC. (PMVP) reported Increase (Decrease) in Prepaid Expense and Other Assets of -$306.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets · last filed 2026-08-14
- PMV PHARMACEUTICALS, INC. increase (decrease) in prepaid expense and other assets for the quarter ending 2026-06-30 was -$253.00K.
- PMV PHARMACEUTICALS, INC. increase (decrease) in prepaid expense and other assets for the quarter ending 2026-03-31 was -$53.00K.
- PMV PHARMACEUTICALS, INC. increase (decrease) in prepaid expense and other assets for the quarter ending 2025-12-31 was -$915.00K, a 470.45% decline year-over-year.
- PMV PHARMACEUTICALS, INC. increase (decrease) in prepaid expense and other assets for the quarter ending 2025-09-30 was $162.00K, a 82.18% decline year-over-year.
- PMV PHARMACEUTICALS, INC. increase (decrease) in prepaid expense and other assets for fiscal 2025 was -$3.92M, a 246.60% decline from fiscal 2024.
- PMV PHARMACEUTICALS, INC. increase (decrease) in prepaid expense and other assets for fiscal 2024 was $2.67M.
- PMV PHARMACEUTICALS, INC. increase (decrease) in prepaid expense and other assets for fiscal 2023 was -$1.72M, a 194.20% decline from fiscal 2022.
- PMV PHARMACEUTICALS, INC. increase (decrease) in prepaid expense and other assets for fiscal 2022 was $1.83M.
| Period end | Increase (Decrease) in Prepaid Expense and Other Assets 3 month | Increase (Decrease) in Prepaid Expense and Other Assets 6 month | Increase (Decrease) in Prepaid Expense and Other Assets 9 month | Increase (Decrease) in Prepaid Expense and Other Assets 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$253.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-14 | -$306.00K 10-Q · filed 2026-08-14 | -$1.22M derived: sum of 3 quarters · filed 2026-08-14 | -$1.06M derived: sum of 4 quarters · filed 2026-08-14 |
| 2026-03-31 | -$53.00K 10-Q · filed 2026-05-12 | -$968.00K derived: sum of 2 quarters · filed 2026-05-12 | -$806.00K derived: sum of 3 quarters · filed 2026-05-12 | -$885.00K derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-12-31 | -$915.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-06 | -$753.00K derived: sum of 2 quarters · filed 2026-03-06 | -$832.00K derived: sum of 3 quarters · filed 2026-08-14 | -$3.92M 10-K · filed 2026-03-06 |
| 2025-09-30 | $162.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $83.00K derived: sum of 2 quarters · filed 2026-08-14 | -$3.00M 10-Q · filed 2025-11-12 | -$2.76M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-06-30 | -$79.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-14 | -$3.17M 10-Q · filed 2026-08-14 | -$2.92M derived: sum of 3 quarters · filed 2026-08-14 | -$2.01M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-03-31 | -$3.09M 10-Q · filed 2026-05-12 | -$2.84M derived: sum of 2 quarters · filed 2026-05-12 | -$1.93M derived: sum of 3 quarters · filed 2026-05-12 | -$583.00K derived: sum of 4 quarters · filed 2026-05-12 |
| 2024-12-31 | $247.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-06 | $1.16M derived: sum of 2 quarters · filed 2026-03-06 | $2.50M derived: sum of 3 quarters · filed 2026-03-06 | $2.67M 10-K · filed 2026-03-06 |
| 2024-09-30 | $909.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $2.26M derived: sum of 2 quarters · filed 2025-11-12 | $2.43M 10-Q · filed 2025-11-12 | $3.41M derived: sum of 4 quarters · filed 2026-03-06 |
| 2024-06-30 | $1.35M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $1.52M 10-Q · filed 2025-08-07 | $2.50M derived: sum of 3 quarters · filed 2026-03-06 | $2.55M derived: sum of 4 quarters · filed 2026-03-06 |
| 2024-03-31 | $169.00K 10-Q · filed 2025-05-09 | $1.15M derived: sum of 2 quarters · filed 2026-03-06 | $1.20M derived: sum of 3 quarters · filed 2026-03-06 | $554.00K derived: sum of 4 quarters · filed 2026-03-06 |
| 2023-12-31 | $984.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-06 | $1.03M derived: sum of 2 quarters · filed 2026-03-06 | $385.00K derived: sum of 3 quarters · filed 2026-03-06 | -$1.72M 10-K · filed 2026-03-06 |
| 2023-09-30 | $51.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | -$599.00K derived: sum of 2 quarters · filed 2024-11-07 | -$2.71M 10-Q · filed 2024-11-07 | -$3.07M derived: sum of 4 quarters · filed 2025-03-03 |
| 2023-06-30 | -$650.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | -$2.76M 10-Q · filed 2024-08-08 | -$3.13M derived: sum of 3 quarters · filed 2025-03-03 | -$1.24M derived: sum of 4 quarters · filed 2025-03-03 |
| 2023-03-31 | -$2.11M 10-Q · filed 2024-05-09 | -$2.48M derived: sum of 2 quarters · filed 2025-03-03 | -$587.00K derived: sum of 3 quarters · filed 2025-03-03 | -$1.20M derived: sum of 4 quarters · filed 2025-03-03 |
| 2022-12-31 | -$367.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-03 | $1.52M derived: sum of 2 quarters · filed 2025-03-03 | $905.00K derived: sum of 3 quarters · filed 2025-03-03 | $1.83M 10-K · filed 2025-03-03 |
| 2022-09-30 | $1.89M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | $1.27M derived: sum of 2 quarters · filed 2023-11-09 | $2.20M 10-Q · filed 2023-11-09 | $415.00K derived: sum of 4 quarters · filed 2024-02-29 |
| 2022-06-30 | -$616.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-09 | $308.00K 10-Q · filed 2023-08-09 | -$1.47M derived: sum of 3 quarters · filed 2024-02-29 | -$300.00K derived: sum of 4 quarters · filed 2024-02-29 |
| 2022-03-31 | $924.00K 10-Q · filed 2023-05-10 | -$857.00K derived: sum of 2 quarters · filed 2024-02-29 | $316.00K derived: sum of 3 quarters · filed 2024-02-29 | -$62.00K derived: sum of 4 quarters · filed 2024-02-29 |
| 2021-12-31 | -$1.78M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29 | -$608.00K derived: sum of 2 quarters · filed 2024-02-29 | -$986.00K derived: sum of 3 quarters · filed 2024-02-29 | -$38.00K 10-K · filed 2024-02-29 |
| 2021-09-30 | $1.17M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | $795.00K derived: sum of 2 quarters · filed 2022-11-08 | $1.74M 10-Q · filed 2022-11-08 | $4.56M derived: sum of 4 quarters · filed 2023-03-01 |
| 2021-06-30 | -$378.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09 | $570.00K 10-Q · filed 2022-08-09 | $3.39M derived: sum of 3 quarters · filed 2023-03-01 | $3.26M derived: sum of 4 quarters · filed 2023-03-01 |
| 2021-03-31 | $948.00K 10-Q · filed 2022-05-10 | $3.77M derived: sum of 2 quarters · filed 2023-03-01 | $3.64M derived: sum of 3 quarters · filed 2023-03-01 | $3.66M derived: sum of 4 quarters · filed 2023-03-01 |
| 2020-12-31 | $2.82M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-01 | $2.69M derived: sum of 2 quarters · filed 2023-03-01 | $2.71M derived: sum of 3 quarters · filed 2023-03-01 | $2.73M 10-K · filed 2023-03-01 |
| 2020-09-30 | -$129.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-12 | -$109.00K derived: sum of 2 quarters · filed 2021-11-12 | -$85.00K 10-Q · filed 2021-11-12 | $137.00K derived: sum of 4 quarters · filed 2022-03-01 |
| 2020-06-30 | $20.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-13 | $44.00K 10-Q · filed 2021-08-13 | $266.00K derived: sum of 3 quarters · filed 2022-03-01 | |
| 2020-03-31 | $24.00K 10-Q · filed 2021-05-14 | $246.00K derived: sum of 2 quarters · filed 2022-03-01 | ||
| 2019-12-31 | $222.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-01 | $275.00K 10-K · filed 2022-03-01 | ||
| 2019-09-30 | $53.00K 10-Q · filed 2020-11-13 | |||
| 2018-12-31 | $17.00K 10-K · filed 2021-03-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| TENAX THERAPEUTICS, INC. (TENX) | United States | $0.071B | -7.17 |
| Lunai Bioworks Inc. (LNAI) | United States | $0.072B | -0.11 |
| PLIANT THERAPEUTICS, INC. (PLRX) | United States | $0.071B | -0.76 |
| Yarrow Bioscience, Inc. (YARW) | United States | $0.070B | |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Connect Biopharma Holdings Ltd (CNTB) | $0.069B | -2.17 | |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |